Citigroup Inc Kezar Life Sciences, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 10,208 shares of KZR stock, worth $5,512. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,208

Previous 15,599 34.56%

Holding current value

$5,512

Previous $14,000 57.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.6 - $0.92 $3,234 - $4,959	-5,391 Reduced 34.56%	10,208 $6,000
Q1 2024 May 10, 2024	BUY	$0.8 - $1.05 $3,864 - $5,071	4,830 Added 44.85%	15,599 $14,000
Q4 2023 Feb 09, 2024	BUY	$0.72 - $1.15 $7,054 - $11,267	9,798 Added 1009.06%	10,769 $10,000
Q3 2023 Nov 09, 2023	SELL	$1.08 - $2.54 $23,235 - $54,645	-21,514 Reduced 95.68%	971 $1,000
Q2 2023 Aug 10, 2023	SELL	$2.31 - $3.06 $410,498 - $543,777	-177,705 Reduced 88.77%	22,485 $55,000
Q1 2023 May 11, 2023	BUY	$3.13 - $7.31 $146,615 - $342,415	46,842 Added 30.55%	200,190 $626,000
Q4 2022 Feb 09, 2023	SELL	$6.39 - $8.8 $447,274 - $615,964	-69,996 Reduced 31.34%	153,348 $1.08 Million
Q3 2022 Nov 10, 2022	BUY	$7.99 - $10.75 $1.74 Million - $2.34 Million	218,052 Added 4120.41%	223,344 $1.92 Million
Q2 2022 Aug 10, 2022	SELL	$4.58 - $17.13 $82,041 - $306,849	-17,913 Reduced 77.19%	5,292 $44,000
Q1 2022 May 12, 2022	SELL	$12.3 - $18.33 $497,781 - $741,815	-40,470 Reduced 63.56%	23,205 $386,000
Q4 2021 Feb 10, 2022	BUY	$7.44 - $16.72 $426,698 - $958,925	57,352 Added 907.04%	63,675 $1.07 Million
Q3 2021 Nov 10, 2021	BUY	$4.85 - $9.73 $30,666 - $61,522	6,323 New	6,323 $55,000

Others Institutions Holding KZR

# of Institutions

Shares Held

39.6M

Call Options Held

3.2K

Put Options Held

700

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $36.9M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account